Evidence map›Paper›PMID 41954764›Full record

Trial reportEuropean journal of pediatrics2026

Melatonin effects on the left ventricular function in neonates with persistent pulmonary hypertension.

Sarah M Nofal, Abdel-Rahman M El-Mashad, Asmaa M Elmesiry, Amany M Abouelenain, Mostafa M Awny

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07090720 (Melatonin Effects on the Left Ventricular Function in Neonates With Persistent Pulmonary Hypertension), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07090720 nacompletednot on this map

Melatonin Effects on the Left Ventricular Function in Neonates With Persistent Pulmonary Hypertension

TypeinterventionalSponsorTanta UniversityRan2023 to 2025Enrolled80ConditionsMelatonin, Left Ventricular Function, Neonates, Persistent Pulmonary HypertensionArmsMelatonin, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sarah M NofalPediatric and Neonatology Department, Faculty of Medicine, Tanta University, El Bahr St., Tanta Qism 2, First Tanta, Gharbia Governorate, Tanta, 31111, Egypt.
Abdel-Rahman M El-MashadPediatric and Neonatology Department, Faculty of Medicine, Tanta University, El Bahr St., Tanta Qism 2, First Tanta, Gharbia Governorate, Tanta, 31111, Egypt.
Asmaa M ElmesiryPediatric and Neonatology Department, Faculty of Medicine, Tanta University, El Bahr St., Tanta Qism 2, First Tanta, Gharbia Governorate, Tanta, 31111, Egypt. asmaa.elmesery@med.tanta.edu.eg.ORCID http://orcid.org/0000-0002-5474-1424
Amany M AbouelenainClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Mostafa M AwnyPediatric and Neonatology Department, Faculty of Medicine, Tanta University, El Bahr St., Tanta Qism 2, First Tanta, Gharbia Governorate, Tanta, 31111, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study is to investigate the effects of melatonin on the left ventricular (LV) function in persistent pulmonary hypertension of the newborn (PPHN) and to assess its potential role in enhancing cardiac performance and reducing oxidative stress. This randomized controlled trial was conducted on 80 neonates (≥ 36 weeks' gestational age) with PPHN confirmed by echocardiography (Echo). Participants were assigned to receive standard therapy alone or in combination with oral melatonin. LV function was evaluated using echocardiographic parameters, and levels of serum biomarkers of oxidative stress and inflammation were also measured. Unlike the placebo group, the melatonin group exhibited significantly better LV function, regarding the conventional and advanced echocardiographic parameters. Additionally, melatonin administration was associated with earlier weaning from mechanical ventilation (MV) and respiratory support, shorter hospital stays, lower levels of serum high-mobility group box-1 (HMGB1) protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP).

conclusionMelatonin can enhance LV function in PPHN, likely through its cardioprotective and antioxidative mechanisms. These findings support melatonin as a promising adjunctive therapy in neonatal pulmonary hypertension, warranting further investigation in larger clinical trials.

trial registrationregistered on ClinicalTrials.gov (ID: NCT07090720), URL: https://clinicaltrials.gov/study/NCT07090720?cond=NCT07090720&rank=1 , Date: (29/7/2025). WHAT IS KNOWN: • PPHN induces hypoxic respiratory failure, jeopardizing multiorgan function, including LV performance. • Oxidative stress is crucial in pulmonary arterial hypertension development. WHAT IS NEW: • Melatonin's antioxidant and vasodilatory properties may serve as an adjunctive therapy in PPHN and enhance myocardial protection from the hypoxic effect of PPHN.

Indexed as

AntioxidantsMelatoninPersistent Fetal Circulation SyndromeVentricular Function, LeftBiomarkersEchocardiographyFemaleHumansInfant, NewbornMaleNatriuretic Peptide, BrainOxidative StressTreatment OutcomeAntioxidantsBiomarkersMelatoninNatriuretic Peptide, BrainAdvanced echocardiographyCardiac biomarkersLeft ventricular functionMelatoninPersistent pulmonary hypertension

Identifiers

PMID41954764
PMCPMC13065569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.